CompletedPhase 4

Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus

Hong Kong72 participantsStarted 2006-06

Plain-language summary

The purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 18 years
✓. Fulfillment of at least 4 of the American College of Rheumatology (ACR) criteria for SLE
✓. Presence of any two of the following risk factors:
✓. Informed consent obtained

Exclusion criteria

✕. Patients with known allergy to aspirin, or any other non-steroidal anti-inflammatory drugs (NSAIDs), or statins
✕. Patient with a history of severe gastrointestinal intolerance to aspirin (e.g., gastrointestinal bleeding) or other NSAIDs
✕. Patients with history of arterial or venous thromboembolism
✕. Patients receiving aspirin or other anti-platelet agents
✕. Patients receiving long-term non-aspirin NSAIDs
✕. Patients receiving anticoagulation therapy (e.g., warfarin)
✕. Patients with history of intolerance or allergy to the statins
✕. Pregnant or lactating women

What they're measuring

endothelial activation markers

Timeframe: 12 months

Trial details

NCT IDNCT00371501

SponsorTuen Mun Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2009-12

View on ClinicalTrials.gov More Atherosclerosis trials